FSS enrols first patients in FlexStent studies
Flexible Stenting Solutions (FSS) has enrolled the first patients in two trials of its FlexStent, a femoropopliteal stent and delivery system.
Flexible Stenting Solutions (FSS) has enrolled the first patients in two trials of its FlexStent, a femoropopliteal stent and delivery system.
The two trials are the Japan FlexStent clinical trial and the US FlexStent OPEN trial in Belgium.
The prospective, multicentre and randomised Japan FlexStent clinical trial will enrol 100 patients and compare the FlexStent with balloon angioplasty.
The company hopes that the system will improve patient care in the high growth peripheral vascular segment.